IMR Press / FBL / Volume 18 / Issue 3 / DOI: 10.2741/4145

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review
Bone marrow mesenchymal stem cells in hepatocellular carcinoma
Show Less
1 Department of Hepatobiliary Surgery, the First Affiliated Hospital of Dalian Medical University, Dalian, China
Academic Editor:Wei Qin
Front. Biosci. (Landmark Ed) 2013, 18(3), 811–819;
Published: 1 June 2013
(This article belongs to the Special Issue Pathogenesis and diagnostic modalities in cancer)

Bone marrow mesenchymal stem cells (BMSCs) are non-hematopoietic multipotent stem cells capable of differentiating into mature cells. Studies in animal models have indicated that hepatocellular carcinoma (HCC) may originate from genetically mutated BMSCs. Moreover, it has been shown that BMSCs are influenced by and can modulate their micro-environment via secreted cytokines that promote tumor initiation, growth, and homing to tumor sites. Based on these features, BMSCs have been recognized as a putative target of molecular therapies to treat and prevent HCC. In this review we discuss the role of human BMSCs in HCC pathogenesis and their therapeutic potential.

Bone marrow mesenchymal stem cells
hepatocellular carcinoma
vascular endothelial cell growth factor
Back to top